Nanotechnology Applications for Glioblastoma
Glioblastoma remains one of the most difficult cancers to treat and represents the most common primary malignancy of the brain. Although conventional treatments have found modest success in reducing the…
Clinical Trials of Small Molecule Inhibitors in High-Grade Glioma
High-grade gliomas are rapidly progressing and generally fatal neoplasms of the brain. Chemotherapy has continued to provide only limited benefit for patients harboring these tumors. The recurrence of common mutations,…
Molecular Characteristics and Pathways of Avastin for the Treatment of Glioblastoma Multiforme
This article provides historical background and current research involving the use of bevacizumab for the treatment of recurrent glioblastoma. Although bevacizumab, approved by the Food and Drug Administration, prolongs glioblastoma…
Potential Usefulness of Radiosensitizers in Glioblastoma
High-grade glioma continues to impart poor prognosis in spite of maximal treatment. Attempted gross total surgical resection followed by concurrent temozolomide and radiation therapy has become standard of care for…
CD133 as a Marker for Regulation and Potential for Targeted Therapies in Glioblastoma Multiforme
The CD133 epitope has been identified as a tumor marker for the purification of a subpopulation of glioblastoma multiforme (GBM) cells demonstrating cancer stem cell phenotypes. Isolated tumorsphere-forming CD133 +…
Potential Role for STAT3 Inhibitors in Glioblastoma
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor. Signal transducers and activators of transcription 3 (STAT3) is a transcription factor that translocates to the nucleus to…
Glioblastoma Multiforme Treatment with Clinical Trials for Surgical Resection (Aminolevulinic Acid)
5-Aminolevulinic acid (5-ALA)-induced tumor fluorescence can be used to identify tissue for resection using an adapted operating microscope. A multi-institutional clinical trial comparing fluorescence-guided versus white light tumor resection reported…
Immunotherapy for Glioma
Novel immunotherapeutic modalities are being pursed in the treatment of high-grade gliomas. This article explains how tumors suppress immune function in the brain. It specifically describes the ways in which…
Modern Management of High Grade Glioma, Part II
Isaac Yang, MD, Guest Editor Seunggu J. Han, MD, Guest Editor Malignant glioblastoma is the most common primary brain tumor and has a poor prognosis. On average, overall survival is…
Management Options for Persistent Postoperative Acromegaly
This article presents management options for the patient with acromegaly after noncurative surgery. The current evidence for repeat surgery, adjuvant medical therapy with somatostatin analogues, dopamine agonists, the growth hormone…
